Insights from 2023 EHA® Annual Meeting

 

Insights from 2023 EHA® Annual Meeting
O

EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously Untreated CLL - 6-Year Results of the Randomized CLL14 Study"

By Insights from 2023 EHA® Annual Meeting FEATURING Othman Al-Sawaf
By Insights from 2023 EHA® Annual Meeting FEATURING Othman Al-Sawaf
670 views
July 17, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal
Leukemia
10:42

Updated Data for Ziftomenib in Adults With NPM1-Mutated R/R AML

Insights from 2023 EHA® Annual Meeting

A. Fathi

241 views
16:16

Experts Discuss Key Updates in CLL From EHA and iCML

Insights from 2023 EHA® Annual Meeting

S. O'Brien, C. Coombs

446 views
06:28

EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously Untrea…

Insights from 2023 EHA® Annual Meeting

O. Al-Sawaf

670 views
07:51

EHA® 2023 Insights: "4-Year Follow-Up From the Randomized Phase 2 VI…

Insights from 2023 EHA® Annual Meeting

A. Kater

82 views